Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea
· Delayed Price · Currency is KRW 5,190.00
-30.00 (-0.57%)
At close: Mar 28, 2025, 3:30 PM KST
Sinsin Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 106,388 | 102,586 | 91,926 | 74,008 | 67,129 | Upgrade
|
| Other Revenue | -0 | -0 | - | -0 | - | Upgrade
|
| Revenue | 106,388 | 102,586 | 91,926 | 74,008 | 67,129 | Upgrade
|
| Revenue Growth (YoY) | 3.71% | 11.60% | 24.21% | 10.25% | -1.07% | Upgrade
|
| Cost of Revenue | 70,278 | 69,274 | 61,706 | 52,318 | 48,708 | Upgrade
|
| Gross Profit | 36,110 | 33,312 | 30,220 | 21,689 | 18,421 | Upgrade
|
| Selling, General & Admin | 27,385 | 25,726 | 23,770 | 21,277 | 20,967 | Upgrade
|
| Research & Development | 474.5 | 488.03 | 89.9 | 709.07 | 785.21 | Upgrade
|
| Other Operating Expenses | 240.35 | 220.94 | 228.42 | 220.21 | 276.09 | Upgrade
|
| Operating Expenses | 29,220 | 27,308 | 24,794 | 23,032 | 22,591 | Upgrade
|
| Operating Income | 6,890 | 6,004 | 5,426 | -1,343 | -4,170 | Upgrade
|
| Interest Expense | -1,960 | -1,937 | -1,481 | -963.24 | -893.62 | Upgrade
|
| Interest & Investment Income | 37.83 | 40.34 | 8.3 | 2 | 15.55 | Upgrade
|
| Currency Exchange Gain (Loss) | 404.45 | 19.14 | 277.35 | 242.67 | -201.51 | Upgrade
|
| Other Non Operating Income (Expenses) | 84.44 | -131.88 | -222.32 | 331.37 | 398.98 | Upgrade
|
| EBT Excluding Unusual Items | 5,457 | 3,995 | 4,009 | -1,730 | -4,850 | Upgrade
|
| Gain (Loss) on Sale of Investments | -323.41 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 7 | -0 | 38.55 | 0.73 | 4,581 | Upgrade
|
| Asset Writedown | - | - | - | -18.16 | - | Upgrade
|
| Pretax Income | 5,141 | 3,995 | 4,047 | -1,747 | -269.32 | Upgrade
|
| Income Tax Expense | 329.15 | -651.57 | -308.12 | -297.73 | -470.61 | Upgrade
|
| Earnings From Continuing Operations | 4,811 | 4,646 | 4,355 | -1,449 | 201.29 | Upgrade
|
| Minority Interest in Earnings | 77.05 | 33.77 | 59.32 | -26.47 | 161.37 | Upgrade
|
| Net Income | 4,888 | 4,680 | 4,415 | -1,476 | 362.66 | Upgrade
|
| Net Income to Common | 4,888 | 4,680 | 4,415 | -1,476 | 362.66 | Upgrade
|
| Net Income Growth | 4.46% | 6.01% | - | - | -83.03% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | Upgrade
|
| Shares Change (YoY) | -0.08% | 0.16% | - | - | - | Upgrade
|
| EPS (Basic) | 322.00 | 308.00 | 291.00 | -97.29 | 23.91 | Upgrade
|
| EPS (Diluted) | 322.00 | 308.00 | 291.00 | -97.29 | 23.91 | Upgrade
|
| EPS Growth | 4.54% | 5.84% | - | - | -83.03% | Upgrade
|
| Free Cash Flow | 4,439 | -1,081 | 4,553 | -2,659 | -10,104 | Upgrade
|
| Free Cash Flow Per Share | 292.38 | -71.16 | 300.15 | -175.28 | -666.04 | Upgrade
|
| Gross Margin | 33.94% | 32.47% | 32.87% | 29.31% | 27.44% | Upgrade
|
| Operating Margin | 6.48% | 5.85% | 5.90% | -1.81% | -6.21% | Upgrade
|
| Profit Margin | 4.59% | 4.56% | 4.80% | -1.99% | 0.54% | Upgrade
|
| Free Cash Flow Margin | 4.17% | -1.05% | 4.95% | -3.59% | -15.05% | Upgrade
|
| EBITDA | 11,150 | 9,941 | 9,184 | 2,329 | -1,586 | Upgrade
|
| EBITDA Margin | 10.48% | 9.69% | 9.99% | 3.15% | -2.36% | Upgrade
|
| D&A For EBITDA | 4,260 | 3,937 | 3,758 | 3,672 | 2,584 | Upgrade
|
| EBIT | 6,890 | 6,004 | 5,426 | -1,343 | -4,170 | Upgrade
|
| EBIT Margin | 6.48% | 5.85% | 5.90% | -1.81% | -6.21% | Upgrade
|
| Effective Tax Rate | 6.40% | - | - | - | - | Upgrade
|
| Advertising Expenses | 4,207 | 4,340 | 4,188 | 3,417 | 3,267 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.